Key facts
- This page summarizes Julie Saiki's Form 4 filing for Azora Therapeutics, Inc. (DE) (AZR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2026, 16:53.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Additional SEC filing notes
Footnote F1
Subject to certain beneficial ownership and other limits set forth in the Certificate of Designation of the Series A Preferred Stock, each share of Series A Preferred Stock converted into 1,000 shares of the Issuer's common stock and has no expiration date.
Footnote F2
The Series A Preferred Stock converted automatically within three days of Issuer's stockholders approving a proposal for the issuance of Issuer common stock upon conversion of the Series A Preferred Stock pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer, Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer, and a private Delaware corporation that was then known as Azora Therapeutics, Inc.